Table 5 Clinical performance of HPV16 and 18 antibody positivity as diagnostic markers for cervical cancer by HIV-status
Serology markers | HIV-positive | HIV-negative | ||||
|---|---|---|---|---|---|---|
Sensitivity (95% CI) | Specificity (95% CI) | AUC | Sensitivity (95% CI) | Specificity (95% CI) | AUC | |
HPV16 E6 | 26.8 (23.5–30.3) | 97.6 (96.1–98.6) | 62 | 42.7 (38.9–46.5) | 95.6 (94.5–96.4) | 69 |
HPV16 E7 | 15.5 (12.9–18.5) | 96.7 (95.0–97.9) | 56 | 30.4 (27.0–34.1) | 96.0 (95.0–96.8) | 63 |
HPV16 E6 & E7 | 12.4 (9.6–15.5) | 99.5 (98.6–99.9) | 56 | 30.9 (26.7–35.2) | 99.5(99.1–99.8) | 65 |
HPV18 E6 | 7.1 (5.3–9.3) | 98.5 (97.3–99.3) | 53 | 10.7 (8.5–13.3) | 97.6 (96.8–98.3) | 54 |
HPV18 E7 | 11.5 (9.2–14.2) | 97.9 (95.2–98.0) | 54 | 23.4 (20.3–26.8) | 97.1 (96.4–97.7) | 60 |
HPV18 E6 & E7 | 3.4 (2.1–5.2) | 99.8 (99.1–100) | 52 | 8.3 (6.1–11.0) | 99.9 (99.5–99.9) | 54 |
HPV16/18 E6/E7 | 43.0 (39.3–46.9) | 90.6 (88.1–92.7) | 67 | 70.6 (67.0–74.0) | 89.7(88.2–91.0) | 80 |